The Zacks Analyst Blog Highlights Exxon Mobil, Palantir, AstraZeneca, Gencor Industries and Hour Loop

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Sales of key drug Farxiga are expected to decline in some countries in 2026 due to generic competition

  80% confidence

• AstraZeneca expects to generate $80 billion in total revenues by 2030

  80% confidence

• Exxon Mobil's high-value assets in the Permian Basin and Guyana drive robust production growth, doubling upstream earnings since 2019

  80% confidence

• Palantir's reluctance to pay dividends is a green flag for dividend-seeking investors

  80% confidence

• Hour Loop remains overly reliant on Amazon (99% of sales), heightening platform risk

  80% confidence

• Crude prices are expected to remain under pressure this year, affecting upstream earnings

  80% confidence

• Since 2000, Zacks top stock-picking strategies have blown away the S&P's +7.7% average gain per year with average gains of +48.4%, +50.2% and +56.7% per year

  80% confidence

Cited in these Via News reports

• AMD Processors Now Accelerate Xanadu's PennyLane Quantum Software Platform →
• Microsoft, Palantir Deploy AI Agents in Live Enterprise Operations as Global Automation Wave Hits Production →
• NVIDIA Signs Six Enterprise Partners for AI Agent Platform, Challenging Microsoft and Google Ecosystems →